Bridgeway Capital Management, LLC Cidara Therapeutics, Inc. Transaction History

Bridgeway Capital Management, LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$1.01 - $1.42 $60,660 - $85,285	60,060 New	60,060 $67,000
Q3 2022 Nov 14, 2022	SELL	$0.45 - $13.0 $45,000 - $1.3 Million	-100,000 Reduced 41.67%	140,000 $88,000
Q2 2022 Aug 15, 2022	SELL	$0.43 - $0.91 $4,300 - $9,100	-10,000 Reduced 4.0%	240,000 $117,000
Q1 2022 May 16, 2022	SELL	$0.67 - $1.39 $65,124 - $135,108	-97,200 Reduced 28.0%	250,000 $208,000
Q4 2021 Feb 14, 2022	BUY	$1.18 - $2.18 $269,419 - $497,741	228,322 Added 192.06%	347,200 $441,000
Q2 2021 Aug 16, 2021	SELL	$1.87 - $2.7 $84,150 - $121,500	-45,000 Reduced 27.46%	118,878 $240,000
Q1 2021 May 17, 2021	SELL	$2.06 - $3.01 $247,162 - $361,145	-119,982 Reduced 42.27%	163,878 $436,000
Q4 2020 Feb 16, 2021	BUY	$1.99 - $3.25 $212,643 - $347,282	106,856 Added 60.37%	283,860 $568,000
Q2 2020 Aug 14, 2020	BUY	$2.39 - $4.0 $119,500 - $200,000	50,000 Added 39.37%	177,004 $653,000
Q1 2020 May 15, 2020	BUY	$1.74 - $4.26 $41,276 - $101,055	23,722 Added 22.97%	127,004 $315,000
Q4 2019 Feb 14, 2020	BUY	$1.77 - $3.84 $15,753 - $34,176	8,900 Added 9.43%	103,282 $397,000
Q1 2019 May 15, 2019	BUY	$2.35 - $3.27 $70,500 - $98,100	30,000 Added 46.6%	94,382 $250,000
Q4 2018 Feb 14, 2019	SELL	$2.1 - $4.5 $240,697 - $515,781	-114,618 Reduced 64.03%	64,382 $151,000
Q3 2018 Nov 13, 2018	BUY	$3.7 - $5.25 $314,500 - $446,250	85,000 Added 90.43%	179,000 $788,000
Q4 2017 Feb 14, 2018	BUY	$6.35 - $8.75 $158,750 - $218,750	25,000 Added 36.23%	94,000 $639,000
Q3 2017 Nov 14, 2017	BUY	$5.75 - $8.1 $396,750 - $558,900	69,000	69,000 $559,000

Ticker CDTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,075,696
Market Cap $1.24B
Description
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.